NASDAQ:DRRX DURECT (DRRX) Stock Forecast, Price & News $2.63 -0.06 (-2.23%) (As of 09/26/2023 ET) Add Compare Share Share Today's Range$2.57▼$2.8450-Day Range$2.63▼$4.9252-Week Range$2.57▼$9.50Volume631,590 shsAverage Volume160,692 shsMarket Capitalization$72.59 millionP/E RatioN/ADividend YieldN/APrice Target$34.25 ProfileProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainabilityProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial MediaSustainability DURECT MarketRank™ ForecastAnalyst RatingBuy3.00 Rating ScoreUpside/Downside1,202.3% Upside$34.25 Price TargetShort InterestBearish7.99% of Float Sold ShortDividend StrengthN/ASustainability-1.19Upright™ Environmental ScoreNews Sentiment1.25Based on 2 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($1.76) to ($1.48) Per ShareSee Full Details Hide Full Details Overall MarketRank™MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.2.07 out of 5 starsMedical Sector569th out of 964 stocksPharmaceutical Preparations Industry252nd out of 445 stocks 3.5 Analyst's Opinion Consensus RatingDURECT has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 4 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $34.25, DURECT has a forecasted upside of 1,202.3% from its current price of $2.63.Amount of Analyst CoverageDURECT has only been the subject of 3 research reports in the past 90 days. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.99% of the float of DURECT has been sold short.Short Interest Ratio / Days to CoverDURECT has a short interest ratio ("days to cover") of 9.7.Change versus previous monthShort interest in DURECT has recently increased by 19.23%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldDURECT does not currently pay a dividend.Dividend GrowthDURECT does not have a long track record of dividend growth. Previous Next 4.4 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreDURECT has received a 67.95% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is driven by its "Clinical research services for physiological diseases " and "Clinical research services for substance abuse disorders " products. See details.Environmental SustainabilityThe Environmental Impact score for DURECT is -1.19. Previous Next 3.5 News and Social Media Coverage News SentimentDURECT has a news sentiment score of 1.25. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.64 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for DURECT this week, compared to 1 article on an average week.Search InterestOnly 5 people have searched for DRRX on MarketBeat in the last 30 days. This is a decrease of -50% compared to the previous 30 days.MarketBeat Follows6 people have added DURECT to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, DURECT insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 4.30% of the stock of DURECT is held by insiders.Percentage Held by InstitutionsOnly 32.82% of the stock of DURECT is held by institutions. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for DURECT are expected to grow in the coming year, from ($1.76) to ($1.48) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of DURECT is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of DURECT is -1.71, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioDURECT has a P/B Ratio of 2.39. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here About DURECT (NASDAQ:DRRX) StockDURECT Corporation, a biopharmaceutical company, researches and develops medicines based on its epigenetic regulator and pharmaceutical programs. The company offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. It also develops larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in Japan, Europe, and internationally. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Read More DRRX Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DRRX Stock News HeadlinesSeptember 18, 2023 | americanbankingnews.comDURECT Co. (NASDAQ:DRRX) Forecasted to Earn Q3 2023 Earnings of ($0.42) Per ShareSeptember 17, 2023 | americanbankingnews.comShort Interest in DURECT Co. (NASDAQ:DRRX) Rises By 19.2%September 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.September 17, 2023 | americanbankingnews.comDURECT (NASDAQ:DRRX) Rating Lowered to Sell at StockNews.comSeptember 14, 2023 | msn.comNorthland sees DURECT's upcoming data as "major" catalyst for stockSeptember 14, 2023 | seekingalpha.comNorthland sees DURECT's upcoming data as "major" catalyst for stock (update)September 7, 2023 | finance.yahoo.comDURECT Corporation Announces Last Patient Last Visit in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated HepatitisAugust 31, 2023 | finance.yahoo.comDURECT Corporation Announces Presentations in Upcoming Investor ConferencesSeptember 27, 2023 | Behind the Markets (Ad)66,000% upside on tiny biotech?The Wall Street Journal reports that this medical breakthrough is "Transforming Medicine." One analyst calculated that it could be worth $1 Trillion, making the upside potential of this small-cap 66,000% above today's price.August 11, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Durect (DRRX) and Cytokinetics (CYTK)August 11, 2023 | msn.comCantor Fitzgerald Maintains Durect (DRRX) Overweight RecommendationAugust 11, 2023 | msn.comHC Wainwright & Co. Maintains Durect (DRRX) Buy RecommendationAugust 9, 2023 | msn.comDURECT GAAP EPS of -$0.46 beats by $0.02, revenue of $2.08M misses by $1.08MAugust 9, 2023 | finance.yahoo.comDURECT Corporation Reports Second Quarter 2023 Financial Results and Business UpdateAugust 8, 2023 | benzinga.comEarnings Outlook For DurectAugust 3, 2023 | finance.yahoo.comDURECT Corporation to Announce Second Quarter 2023 Financial Results and Provide a Business UpdateJuly 20, 2023 | msn.comU.S. stocks mixed at close of trade; Dow Jones Industrial Average up 0.47%July 20, 2023 | marketwatch.comDurect Shares Slide Premarket on Planned Stock Sale >DRRXJuly 20, 2023 | finance.yahoo.comDURECT Corporation Announces $15 Million Registered Direct Offering Priced At-The-Market Under Nasdaq RulesJune 7, 2023 | finance.yahoo.comDURECT Completes Enrollment in Phase 2b AHFIRM Trial of Larsucosterol in Alcohol-Associated HepatitisMay 18, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Durect (DRRX), Pfizer (PFE) and BioVie (BIVI)May 17, 2023 | msn.comCantor Fitzgerald Reiterates Durect (DRRX) Overweight RecommendationMay 17, 2023 | markets.businessinsider.comAnalyst Ratings for DurectMay 17, 2023 | marketwatch.com8-K: DURECT CORPMay 12, 2023 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Durect (DRRX), MacroGenics (MGNX) and Precision BioSciences (DTIL)May 11, 2023 | finance.yahoo.comWall Street Analysts Think Durect (DRRX) Could Surge 594.98%: Read This Before Placing a BetMay 10, 2023 | washingtonpost.comDurect: Q1 Earnings SnapshotSee More Headlines Receive DRRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for DURECT and its competitors with MarketBeat's FREE daily newsletter. Email Address DRRX Company Calendar Last Earnings8/09/2023Today9/27/2023Next Earnings (Estimated)11/01/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:DRRX CUSIPN/A CIK1082038 Webwww.durect.com Phone(408) 777-1417Fax408-777-3577Employees72Year FoundedN/APrice Target and Rating Average Stock Price Forecast$34.25 High Stock Price Forecast$41.00 Low Stock Price Forecast$27.00 Forecasted Upside/Downside+1,202.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage4 Analysts Profitability EPS (Most Recent Fiscal Year)($1.54) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-35,330,000.00 Net Margins-185.87% Pretax Margin-185.87% Return on Equity-179.02% Return on Assets-61.31% Debt Debt-to-Equity RatioN/A Current Ratio0.97 Quick Ratio0.92 Sales & Book Value Annual Sales$19.28 million Price / Sales3.76 Cash FlowN/A Price / Cash FlowN/A Book Value$1.10 per share Price / Book2.39Miscellaneous Outstanding Shares27,600,000Free Float26,413,000Market Cap$72.59 million OptionableOptionable Beta1.49 Beginner's Guide to Pot Stock InvestingClick the link below and we'll send you MarketBeat's guide to pot stock investing and which pot companies show the most promise. Get This Free Report Key ExecutivesDr. James E. Brown D.V.M. (Age 66)Co-Founder, CEO, Pres & Director Comp: $885.86kMs. Judy R. Joice (Age 66)Sr. VP of Operations & Corp. Quality Assurance Comp: $451.82kDr. Norman L. Sussman M.D. (Age 70)Chief Medical Officer Comp: $587.95kMr. Timothy M. Papp M.B.A. (Age 47)CFO & Sec. Ms. Jian Li M.B.A. (Age 53)Interim Principal Accounting Officer, Sr. VP of Fin., Corp. Controller & Sec. Dr. WeiQi Lin M.D.Ph.D., Exec. VP of R&D and Principal ScientistMr. Keith L. Lui M.B.A.Sr. VP of Bus. Devel., Commercial & Medical AffairsDr. Su Il Yum Ph.D. (Age 84)Exec. Officer More ExecutivesKey CompetitorsKronos BioNASDAQ:KRONVeruNASDAQ:VERUCorvus PharmaceuticalsNASDAQ:CRVSSCYNEXISNASDAQ:SCYXProPhase LabsNASDAQ:PRPHView All CompetitorsInstitutional OwnershipWolverine Trading LLCBought 4,700 shares on 8/23/2023Ownership: 0.000%Citadel Advisors LLCBought 11,900 shares on 8/15/2023Ownership: 0.000%State Street CorpBought 5,239 shares on 8/14/2023Ownership: 0.298%Caption Management LLCBought 43,400 shares on 8/14/2023Ownership: 0.000%Geode Capital Management LLCBought 15,919 shares on 8/11/2023Ownership: 0.946%View All Institutional Transactions DRRX Stock - Frequently Asked Questions Should I buy or sell DURECT stock right now? 4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for DURECT in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" DRRX shares. View DRRX analyst ratings or view top-rated stocks. What is DURECT's stock price forecast for 2023? 4 brokerages have issued twelve-month price targets for DURECT's shares. Their DRRX share price forecasts range from $27.00 to $41.00. On average, they anticipate the company's stock price to reach $34.25 in the next twelve months. This suggests a possible upside of 1,202.3% from the stock's current price. View analysts price targets for DRRX or view top-rated stocks among Wall Street analysts. How have DRRX shares performed in 2023? DURECT's stock was trading at $3.46 at the beginning of 2023. Since then, DRRX stock has decreased by 24.0% and is now trading at $2.63. View the best growth stocks for 2023 here. When is DURECT's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Wednesday, November 1st 2023. View our DRRX earnings forecast. How were DURECT's earnings last quarter? DURECT Co. (NASDAQ:DRRX) announced its quarterly earnings data on Wednesday, August, 9th. The specialty pharmaceutical company reported ($0.46) EPS for the quarter, missing analysts' consensus estimates of ($0.45) by $0.01. The specialty pharmaceutical company earned $2.08 million during the quarter, compared to analyst estimates of $2.89 million. DURECT had a negative net margin of 185.87% and a negative trailing twelve-month return on equity of 179.02%. When did DURECT's stock split? DURECT shares reverse split on the morning of Tuesday, December 6th 2022. The 1-10 reverse split was announced on Tuesday, December 6th 2022. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, December 6th 2022. An investor that had 100 shares of stock prior to the reverse split would have 10 shares after the split. What other stocks do shareholders of DURECT own? Based on aggregate information from My MarketBeat watchlists, some companies that other DURECT investors own include Geron (GERN), Catalyst Pharmaceuticals (CPRX), VBI Vaccines (VBIV), MannKind (MNKD), Novavax (NVAX), Cassava Sciences (SAVA), Amarin (AMRN), Matinas BioPharma (MTNB), Inovio Pharmaceuticals (INO) and Verastem (VSTM). What is DURECT's stock symbol? DURECT trades on the NASDAQ under the ticker symbol "DRRX." Who are DURECT's major shareholders? DURECT's stock is owned by a variety of retail and institutional investors. Top institutional investors include Ingalls & Snyder LLC (6.10%), CM Management LLC (1.92%), Renaissance Technologies LLC (1.48%), BlackRock Inc. (1.46%), Beirne Wealth Consulting Services LLC (1.15%) and Geode Capital Management LLC (0.95%). Insiders that own company stock include Gail J Maderis, Gail M Farfel, Judith J Robertson, Judy R Joice, Mohammad Azab and Simon X Benito. View institutional ownership trends. How do I buy shares of DURECT? Shares of DRRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is DURECT's stock price today? One share of DRRX stock can currently be purchased for approximately $2.63. How much money does DURECT make? DURECT (NASDAQ:DRRX) has a market capitalization of $72.59 million and generates $19.28 million in revenue each year. The specialty pharmaceutical company earns $-35,330,000.00 in net income (profit) each year or ($1.54) on an earnings per share basis. How can I contact DURECT? DURECT's mailing address is 10260 BUBB RD, CUPERTINO CA, 95014. The official website for the company is www.durect.com. The specialty pharmaceutical company can be reached via phone at (408) 777-1417, via email at mike.arenberg@durect.com, or via fax at 408-777-3577. This page (NASDAQ:DRRX) was last updated on 9/27/2023 by MarketBeat.com Staff Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding DURECT Co. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.